

Increase Patient Access to **Lower-Cost Biosimilar** Medicines

The U.S. health care system has lost nearly \$2.2 billion in savings due to slow biosimilar adoption since 2015.¹ The three legislative proposals below would help strengthen biosimilar adoption and utilization. Each is designed to ensure savings for patients and Medicare.²

Cosponsor the BIOSIM Act (H.R. 4455)

ENCOURAGE PHYSICIAN USE OF LOWER-COST BIOSIMILARS

- Currently, providers in Medicare Part B are reimbursed for administering biosimilars at ASP+6% of the brand-name biologic.
- The *BIOSIM Act* would **increase reimbursement** for biosimilars by 2% to ASP+8%³ and would apply only when the biosimilar's ASP is lower than the brand-name biologic's ASP.
- Currently, biosimilars have, on average, a 25% lower ASP than their respective reference products.⁴



Cosponsor Biosimilars Shared Savings Demo (H.R. 6179)

INCENTIVE FOR PHYSICIANS, LOWER COSTS FOR PATIENTS, AND SAVINGS FOR MEDICARE

- A voluntary, national demonstration project could be established under Medicare Part B to evaluate the benefits of providing a shared savings payment for biosimilars.
- Participating providers would receive a portion of the **savings for prescribing a biosimilar** with a lower ASP than the brand-name biologic.
- Patients receiving a biosimilar could have a portion of the savings applied to their out-of-pocket costs.
- This program would create a financial incentive to administer biosimilars and guarantees additional savings for Medicare and taxpayers.



Cosponsor the ACCESS Act (H.R. 4597)

REDUCE PATIENT COST-SHARING FOR BIOSIMILARS

- Patients often pay 20 percent of the cost of prescription drugs under Medicare Part B.
- The ACCESS Act would increase patient access to biosimilars by **reducing a patient's out-of-pocket cost.**⁵
- The reduced patient cost-sharing would encourage greater physician use of biosimilars and only applies when the Part B payment for the biosimilar is lower than Part B payment for the brand-name biologic.



¹ <https://biosimilarscouncil.org/news/policy-and-market-failures-stifle-biosimilar-adoption-in-the-u-s/>

² <https://biosimilarscouncil.org/news/congress-bipartisan-efforts-to-increase-patient-access-to-biosimilars/>

³ <https://schrader.house.gov/newsroom/documentsingle.aspx?DocumentID=392607>

⁴ CMS January 2020 ASP Pricing Files

⁵ <https://scottspeters.house.gov/media-center/press-releases/rep-peters-king-brindisi-introduce-bipartisan-bill-to-make-cost-0>

Support of the three legislative proposals described above would be the most impactful in the short-term to the biosimilars market. See how you can increase patient access to lower-cost biosimilar medicines at biosimilarscouncil.org